MD Anderson and their large library of (intracellular) binding sites is where I think this will eventually take off. shellbell or hottod could correct me if I'm wrong, but my layman's impression is that their antibody program is failing not due to lack of efficacy or lack of safety, but lack of persistence. Creating a binder or two or three and plugging it onto Omnicar would seem to solve that problem. Prove the tumour is responsive to the antibody infusion(s), then create the t-cells for as many intracellular binding sites as you would like, with minimal to no collateral damage. if you get antigen escape, try another binder.
all idle speculation on my part, and my interpretation of the science could be wrong, so do your own research.
Daily happenings?., page-118
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.5¢ |
Change
-0.002(4.26%) |
Mkt cap ! $36.23M | |||
| Open | High | Low | Value | Volume |
| 4.8¢ | 4.8¢ | 4.5¢ | $40.19K | 861.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 275278 | 4.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.7¢ | 149532 | 2 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
4.6¢ |
Change
-0.002 ( 2.13 %) |
||||
| Open | High | Low | Volume | ||
| 4.7¢ | 4.7¢ | 4.6¢ | 428792 | ||
| Last updated 14.48pm 21/05/2024 ? | |||||
| PTX (ASX) Chart |